Open an account

Positron

POSC · OTC

$1.72+$0.0228 (+1.34%)TodayMarket closed ·
Prev close $1.70

About POSC

Positron Corp. operates as a nuclear medicine healthcare company, which engages in the provision of cardiac positron emission tomography imaging. The firm specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.

Employees
0
Headquarters
Niagara Falls, Illinois
Listed
Feb 10, 1994
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
positron.com

POSC key statistics

Market cap
56.59M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
24.42K
Volume
13.87K
Open price
$1.70
High today
$1.75
Low today
$1.70
52 Week high
$2.74
52 Week low
$1.27

Positron (POSC) at a glance

Positron (POSC) last traded at $1.72, with a market cap of 56.59M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.70 and $1.75. The current price is 1.3% above the day's low and 1.6% below its high.

Volume so far is 13.87K shares, below the average of 24.42K shares a day.

Over the past year Positron has ranged from $1.27 to $2.74, and now sits 31% of the way up that range.

Positron met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q4 FY98 it reported $20.00 per share against an estimate of $44.88.

POSC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 56.4% on average.

  1. Q1 FY94: reported -$88.00 per share against an estimate of -$81.60
  2. Q2 FY94: reported -$112.00 per share against an estimate of -$73.44
  3. Q4 FY94: reported -$104.00 per share against an estimate of -$762.96
  4. Q2 FY95: reported -$60.00 per share against an estimate of -$81.60
  5. Q3 FY95: reported -$168.00 per share against an estimate of -$73.44
  6. Q4 FY95: reported -$176.00 per share against an estimate of $0.00
  7. Q1 FY96: reported -$228.00 per share against an estimate of -$40.80
  8. Q4 FY98: reported $20.00 per share against an estimate of $44.88

POSC news

  • Press releaseBusiness Wire

    Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO

Similar companies

Companies in the same industry as Positron

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.